Non Obstructive Urinary Retention, Overactive Bladder
Conditions
Keywords
Sacral neuromodulation, Electromyography, Pelvic floor
Brief summary
Prospective observational study. A substantial number of patients do not respond favourably to sacral neurostimulation (SNS) although clinically, they appear to have the same lower urinary tract (LUT) dysfunction characteristics as the good responders. This may be due to methodological issues (lead position) or patient selection. The purpose of this study is to improve and standardize lead position, in order to increase the patient response to test stimulation and to SNS treatment, and to decrease adverse events.
Interventions
DIAGNOSTIC_TESTEMG pelvic floor
EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
Sponsors
Leiden University Medical Center
Universiteit Antwerpen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female aged ≥18 years and competent to provide consent 2. Minimum 3 months of self-reported OAB symptoms or self-reported obstructive lower urinary tract symptoms (LUTS) in addition to confirmed non-obstructive urinary retention on urodynamics. 3. Failed, or are not a candidate for more conservative treatment (i.e., pelvic floor training, biofeedback, behavioral modification, oral pharmacotherapy) 4. Willing to discontinue OAB medications for 2 weeks prior to the implant and for the entire study period 5. Able to thoroughly fill in all questionnaires, voiding diaries and office visits for device programming and clinical evaluations before the TLP, 3 weeks after TLP and 6 weeks, 6 months and 1 year after implantation of definitive IPG.
Exclusion criteria
1. Current of prior evidence of primary stress incontinence or mixed incontinence where the stress component overrides the urgency component 2. Any neurological condition that may interfere with normal bladder function, including stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia) 3. Urinary tract mechanical obstruction including but not limited to Benign Prostatic Hyperplasia (BPH) 4. Treatment of bladder or pelvic floor dysfunction with botulinum toxin (Botox ®) or surgery in past 12 months 5. Unable to toilet self and have and maintain good personal hygiene 6. Unable to provide clear, thoughtful responses to questions and questionnaires 7. Urinary tract, bladder or vaginal infection or inflammation 8. Hematuria, and absence of an elaborate diagnostic work-up 9. Severe or uncontrolled diabetes (A1C \> 8, documented in the last 3 months) or diabetes with peripheral nerve involvement 10. Allergy to local anesthetic or adhesives 11. Bleeding disorder or on an anticoagulant that cannot be stopped for 3 days before the implant 12. Pregnant, lactating, planning to become pregnant, given birth in the past 12 months, or female of child-bearing potential and not practicing a medically-approved method of birth control 13. Skin lesions or compromised skin at the implant or stimulation site 14. Use of investigational drug or device therapy or participation in any study involving or impacting gynecologic, urinary or renal function within past 4 weeks 15. Passive implants (e.g., prostheses) are allowed, but no implanted metal should be at the Neurostimulator implant site 16. Knowledge of planned magnetic resonance imaging (MRI), diathermy, or high output ultrasonic exposure 17. Presence of a documented condition or abnormality that could compromise the safety of the patient 18. Any psychiatric or personality disorder at the discretion of the study physician 19. Interstitial cystitis or bladder pain syndrome as defined by the guidelines of the European Association of Urology (EAU). 20. Life expectancy of less than 1 year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| EMG pelvic floor | 1 day | Latency and amplitude measured by probe |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Voiding diary | 1 year | Determine the success rate of tined lead test period based upon changes in 3 days. |
| Prevalence of adverse events | 2 years | Prevalence of adverse events, which are defined as: pain, decrease in efficacy and number of reprogramming sessions. |
| Validated questionnaires (KHQ and PeLFis) | 1 year | Determine the success rate of tined lead test period based upon changes in validated questionnaires (KHQ and PeLFis). |
Countries
Belgium
Contacts
Primary ContactStefan De Wachter, MD PhD FEBU
Backup ContactDonald Vaganée
Outcome results
None listed